FAS
ALNY icon

Formuepleje A/S’s Alnylam Pharmaceuticals ALNY Stock Holding History

Formuepleje A/S’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-94,653
Closed -$13.8M – 99
2022
Q2 		$13.8M Buy
+94,653
New +$13.4M 0.85% 28

Other funds holding ALNY

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Formuepleje A/S's ALNY Position: Q3 2022 in Review

Formuepleje A/S sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 94,653 shares — an estimated $13.8M sold.

Formuepleje A/S first reported a position in ALNY in Q2 2022 and held it in 1 quarter. The position peaked at $13.8M in Q2 2022. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Formuepleje A/S reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Formuepleje A/S sold 94,653 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $13.8M.
  • Formuepleje A/S first reported a position in Alnylam Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Formuepleje A/S's Alnylam Pharmaceuticals position peaked at $13.8M in Q2 2022.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Formuepleje A/S's 13F filing for Q3 2022, filed 27 Aug 2026.